By / June 16, 2022

Brazilian Supreme Court Approves the Cultivation of Medical Cannabis

While Brazil legalized medical cannabis in late 2019, the Brazilian Ministry of Health has not yet regulated the home cultivation of cannabis for medical purposes. This is leaving patients dependent on expensive imports for their treatments.

And while a bill tabled in August 2020 by deputies Paulo Teixeira and Luciano Ducci that would legalize the cultivation of medical cannabis and industrial hemp could soon be presented to the lower house, delays are leaving patients waiting. This has some patients in Brazil turning to the courts.

Brazilian Supreme Court Authorizes Three Patients

Last Tuesday, the Brazilian Supreme Court of Justice authorized three patients to cultivate cannabis for medical purposes, a decision that should be applied nationwide in similar cases.

A panel of five judges unanimously ruled that the three Brazilian patients could grow cannabis. The cases in question mainly concerned the extraction of cannabidiol to relieve their pain. Brazilian law currently limits the medical use of cannabis-derived products to imported products.

Justice Rogerio Schietti said the Supreme Court panel acted because the Brazilian government had not taken a position on the matter.

Religion and the Far-Right

“The discourse against medical cannabis is moralistic. It often has a religious character, based on dogma, false truths, stigmas,” Judge Schietti said. “Let’s put an end to this prejudice, to this moralism which delays the development of this issue at the legislative level and which very often obscures the minds of Brazilian judges.”

Judge Antonio Saldanha said, “there is a deliberate retrograde move towards obscurantism” in the Brazilian government’s delay.

President Jair Bolsonaro, a far-right politician facing an uphill battle for re-election in October, said in June 2021 that he disagreed with any permission for Brazilians to grow cannabis at home, regardless of their objective.

The majority of Brazilians Support Medical Cannabis

In 2020, former President Luiz Inacio Lula da Silva, the main leader of the left-wing Workers’ Party, was leading all opinion polls to regain the post he held from 2003 to 2010 and is in favor of legalizing cannabis.

The current high price of medical cannabis is one of the main arguments in favor of the cultivation bill. Domestic producers would thus be able to supply medical cannabis at a lower cost.

According to Paulo Teixeira, who headed a special committee on medical cannabis in the Brazilian lower house, the bill has not made progress in the legislative process, leaving many patients stuck.

The Brazilian Cannabis Debate

The MP said the bill was “the result of a long and deep debate which studied the best of different cannabis legislation in other countries”.

At the same time, Brazil is studying the possibility of reimbursing a drug containing CBD. Distributed by the Brazilian pharmaceutical company Prati-Donaduzzi, the treatment today costs €375 and remains unaffordable for many patients. If it was finally reimbursed, the bill would still be paid by the taxpayer, who would ultimately also benefit from the legalization of national cannabis cultivation.

(Featured image by Kindel Media via Pexels)

DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of, its management, staff, or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published by Newsweed, a third-party contributor translated and adapted the articles (article 1, article 2) from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. assumes no responsibility for errors, omissions, or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Comments are closed for this post.